Plain-English translation of NCT06581861 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term research study designed to follow people who have inherited a gene that increases their risk for ALS (a progressive neurological disease) but haven't developed any symptoms yet. By collecting blood samples, health information, and other measurements over 3 years, researchers hope to identify early warning signs that could help prevent or delay the disease. The study is funded by the National Institutes of Health and led by major medical centers across the country.
Most people diagnosed with ALS are already showing symptoms, making treatment much harder. This study aims to catch the disease earlier—before symptoms appear—in people who carry the genetic risk. Understanding what happens in these early, silent stages could lead to new ways to slow down or prevent ALS entirely.
You likely qualify if…
You likely don't qualify if…
Over 3 years, you would have 4 in-person visits at a clinic (one per year) and 6 remote visits via phone or video (every 4 months). At each visit, you'll answer questions about your health, provide blood samples, and may record speech samples. You can also optionally provide cerebrospinal fluid (spinal fluid) through a procedure called a lumbar puncture, and you can choose to have genetic testing with counseling from a genetic specialist. All your samples and information will be kept and made available to other researchers studying ALS and related diseases.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States